Silva Pharmaceuticals Limited announcements
119 Dhaka Stock Exchange announcements for Silva Pharmaceuticals Limited (SILVAPHL) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (29).
- Credit Rating Result
Credit Rating Agency of Bangladesh Limited (CRAB) has assigned Surveillance entity rating of the Company as "BBB1" and "ST-1" in the short term along with Stable outlook based on audited financial statements (FYE 30/06/2025, 30/06/2024, 30/06/2023), bank liability as on 30/11/2025 and other information up to the date of rating declaration.
- Qualified Opinion
The auditor of the company has given the Qualified Opinion in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals%20Limited_2025.pdf
- Resumption after Record Date
Trading of the shares of the company will resume on 07.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 04.12.2025 for EGM.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended 31 October, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SILVAPHL_2025.pdf
- Spot for EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 02.12.2025 to 03.12.2025 and trading of the shares will remain suspended on record date i.e., 04.12.2025 for EGM.
- Resumption after Record Date
Trading of the shares of the company will resume on 02.12.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 01.12.2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 27.11.2025 to 30.11.2025 and trading of the shares will remain suspended on record date i.e., 01.12.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.26) for July-September 2025 as against Tk. (0.24) for July-September 2024; NOCFPS was Tk. 0.15 for July-September 2025 as against Tk. 0.07 for July-September 2024. NAV per share was Tk. 15.22 as on September 30, 2025 and Tk. 15.48 as on June 30, 2025. (cont.1) (cont. news of SILVAPHL): The net loss incurred during the period also contributed to a corresponding decline in Net Asset Value per Share (NAVPS). However, payments to suppliers and other creditors were lower during this period, leading to an increase in Net Operating Cash Flow per Share (NOCFPS) compared to the previous year. (end) (cont. news of SILVAPHL): Reason for deviation in EPS, NAVPS and NOCFPS: During the period, the Company's revenue from sales declined due to significant turnover within the field force sales team and disruptions in the supply chain. Despite the revenue shortfall, fixed operating expenses and finance costs remained consistent with prior levels, resulting in a slight decrease in Earnings per Share (EPS) compared to the previous period. (cont.2)
- EGM to change the name of the company, and other matters
The Board of Directors of the company has taken the following decisions, which are subject to the approval by the Shareholders at the upcoming EGM and BSEC. 1) Change of Company name and Amend the AoA; 2) Post-Facto Approval of Project Revisions; and 3) Revised Proposal for utilization of IPO Proceeds. (cont.) (cont. news of SILVAPHL): Details of the EGM: Date of EGM: 30.12.2025, Time: 10:30 AM, Mode and Venue: Hybrid System (Physical venue will be notified later). Record date: 04.12.2025. To view the details, please visit the link: https://www.dsebd.org/Annexure/2025/SILVA-PHARMACEUTICALS-LIMITED_2025.pdf (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2025 at 3:30 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding "Status of IPO (Initial Public Offering) Proceeds utilization statement" for the month ended September?30,?2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva-Pharmaceuticals-Ltd-2025.pdf
- Dividend Declaration
The Board of Directors has recommended No Dividend for the year ended June 30, 2025. Date of AGM: 30.12.2025; Time: 11:30 AM; Venue/Mode of AGM: Hybrid System (Both Physical and Digital Platform). Record Date: 01.12.2025. The Company has also reported EPS of Tk. (0.97), NAV per share of Tk. 15.48 and NOCFPS of Tk. 0.10 for the year ended June 30, 2025 as against Tk. (0.47), Tk. 16.53 and Tk. 0.03 respectively for the year ended June 30, 2024.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2025 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended 31 August, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals-09252025100206.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended July 31, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SILVAPHARMA_2025.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month ended on June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals%20Ltd_2025.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of May 31, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SilvaPharmaceuticalsLimited2025.pdf
- Auditor's report regarding Status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding "Status of IPO (Initial Public Offering) Proceeds utilization statement" for the month ended 30 April, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals%20Ltd.%20(April)_25.pdf
- Q3 Financials
(Q3 Un-audited): EPS was Tk. (0.14) for January-March 2025 as against Tk. 0.04 for January-March 2024; EPS was Tk. (0.57) for July 2024-March 2025 as against Tk. (0.08) for July 2023-March 2024. NOCFPS was Tk. 0.26 for July 2024-March 2025 as against Tk. 0.24 for July 2023-March 2024. NAV per share was Tk. 15.91 as on March 31, 2025 and Tk. 16.53 as on June 30, 2024. EPS decreased comparison to the same period (cont.) (Continuation news of SILVAPHL): of the previous year due to increase in cost of goods sold for disruption of global supply chain caused increase of all input raw material (Local and imported) price caused by appreciation of US Dollar against BDT, increase of utility cost and other relevant overhead and also decrease in the sales volume as compared to the previous year same period. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2025 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of February 28, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/Silva%20Pharmaceuticals%20Limited_2025.pdf
- Auditor's report regarding status of IPO Proceeds utilization
Silva Pharmaceuticals Limited submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the month of January 31, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/SILVAPHL_2025.pdf
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. (0.19) for October-December 2024 as against Tk. (0.06) for October-December 2023; EPS was Tk. (0.43) for July-December 2024 as against Tk. (0.12) for July-December 2023. NOCFPS was Tk. 0.11 for July-December 2024 as against Tk. 0.17 for July-December 2023. NAV per share was Tk. 16.02 as on December 31, 2024 and Tk. 16.53 as on June 30, 2024. (cont.1) (Continuation news of SILVAPHL): EPS has decreased due to the decline in sales volume and an increase in operating expenses. NAVPS has decreased due to net loss incurred during this period. NOCFPS has decreased compared to the same period of the previous year due to a decrease in the collection from receivables as well as sales. (end) (Continuation news of SILVAPHL): Reasons for Deviation in EPS, NOCFPS and NAVPS: During the period, the net profit after tax decreased compared to the corresponding period of the previous year due to a decline in sales volume. The main reason for the decrease in sales volume is recent flash flooding in some of our important business areas, as well as political unrest and unstable economic conditions across Bangladesh. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Regarding time extension of IPO proceeds utilization
The company has informed that it has extended the time for utilization of IPO proceeds up to December 31, 2025 in its 23rd Annual General Meeting (AGM).
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.